A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore the effect of a new drug (ASP9831) in patients with
non-alcoholic steatohepatitis (NASH) by assessing clinical signs, laboratory data and
biomarkers during a 12 week treatment period